<DOC>
	<DOCNO>NCT00445965</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody , iodine I 131 monoclonal antibody 3F8 , find tumor cell carry tumor-killing substance without harm normal cell . This may effective treatment central nervous system cancer leptomeningeal metastasis . PURPOSE : This phase II trial study side effect well iodine I 131 monoclonal antibody 3F8 work treat patient central nervous system cancer leptomeningeal cancer .</brief_summary>
	<brief_title>Iodine I 131 Monoclonal Antibody 3F8 Treating Patients With Central Nervous System Cancer Leptomeningeal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine intrathecal iodine I 131 monoclonal antibody 3F8 activity patient GD2-expressing central nervous system leptomeningeal neoplasms sufficiently promise ( i.e. , 6-month overall survival rate â‰¥ 25 % ) warrant study . - Determine response rate patient treat drug . - Determine cumulative toxicity drug patient . - Describe effect human-antimouse antibody cerebrospinal fluid serum pharmacokinetics patient treated drug . OUTLINE : This open-label study . Patients receive intrathecal iodine I 131 monoclonal antibody 3F8 dosimetry . Beginning approximately 1 week later , patient receive intrathecal iodine I 131 monoclonal antibody 3F8 day 1 . Treatment intrathecal iodine I 131 monoclonal antibody 3F8 repeat weekly 4 course absence disease progression unacceptable toxicity . Blood cerebrospinal fluid sample collect prior administration course study drug . Samples analyze assess intrathecal blood pharmacokinetics iodine I 131 monoclonal antibody 3F8 serum human antimouse antibody . Samples also analyze tumor genetic study . After completion study treatment , patient follow periodically 3 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>Patients must histologically confirm diagnosis malignancy know expressGD2 . Such tumor include medulloblastoma/primitive neuroectodermal tumor CNS , high grade astrocytomas , malignant glioma , neuroblastoma , retinoblastoma , ependymoma , rhabdoid tumor , sarcoma , melanoma small cell lung carcinoma . For patient tumor type , GD2 expression must confirm immunohistochemical staining assess Department Pathology use prior frozen tissue , bone marrow CSF cytology ( send Research Lab ) . Patients must CNS/ leptomeningeal disease include high risk medulloblastoma , CNS/leptomeningeal malignancy refractory conventional therapy , conventional therapy exists , OR recurrent brain tumor predilection leptomeningeal dissemination ( medulloblastoma , PNET , rhabdoid tumor ) . Patients must absolute neutrophil count ( ANC ) &gt; 1000/ul platelet count &gt; 50,000/ul . Patients may active malignancy outside central nervous system . Patients programmable shunt exclude . Both pediatric adult patient age eligible . Patients legal guardian sign inform consent form approve IRB obtain Principal Co Investigator patient entry . Minors provide assent . Patients obstructive symptomatic communicating hydrocephalus . Patients uncontrolled lifethreatening infection . Patients pregnant : Pregnant woman exclude fear danger fetus . Therefore negative pregnancy test require woman childbearing age , appropriate contraception require study period . Patients receive cranial spinal irradiation le 3 week prior start protocol . Patients receive systemic chemotherapy ( corticosteroid include ) less 3 week prior start protocol . Severe major organ toxicity . Specifically , renal , cardiac , hepatic , pulmonary , gastrointestinal system toxicity less equal grade 2 . Patients stable neurological deficit ( brain tumor ) exclude . Patients &lt; = 3 hearing loss exclude . Patients must rapidly progress deteriorate neurologic examination . Patients already receive &gt; 45 Gy craniospinal radiation &gt; 72 Gy focal brain radiation .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>untreated childhood medulloblastoma</keyword>
	<keyword>adult supratentorial primitive neuroectodermal tumor ( PNET )</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult diffuse astrocytoma</keyword>
	<keyword>adult pilocytic astrocytoma</keyword>
	<keyword>adult subependymal giant cell astrocytoma</keyword>
	<keyword>recurrent childhood subependymal giant cell astrocytoma</keyword>
	<keyword>untreated childhood subependymal giant cell astrocytoma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>untreated childhood cerebellar astrocytoma</keyword>
	<keyword>adult brain stem glioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>childhood mixed glioma</keyword>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>recurrent childhood visual pathway hypothalamic glioma</keyword>
	<keyword>recurrent childhood visual pathway glioma</keyword>
	<keyword>untreated childhood brain stem glioma</keyword>
	<keyword>untreated childhood visual pathway hypothalamic glioma</keyword>
	<keyword>untreated childhood visual pathway glioma</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>extraocular retinoblastoma</keyword>
	<keyword>recurrent retinoblastoma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult ependymoblastoma</keyword>
	<keyword>adult ependymoma</keyword>
	<keyword>adult myxopapillary ependymoma</keyword>
	<keyword>adult subependymoma</keyword>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>adult medulloblastoma</keyword>
	<keyword>chondrosarcoma</keyword>
	<keyword>metastatic osteosarcoma</keyword>
	<keyword>recurrent osteosarcoma</keyword>
	<keyword>metastatic childhood soft tissue sarcoma</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>recurrent childhood soft tissue sarcoma</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
	<keyword>stage III uterine sarcoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>previously treat childhood rhabdomyosarcoma</keyword>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult desmoplastic small round cell tumor</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>tumor metastatic brain</keyword>
	<keyword>adult rhabdomyosarcoma</keyword>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>childhood desmoplastic small round cell tumor</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>intraocular retinoblastoma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>small intestine leiomyosarcoma</keyword>
	<keyword>recurrent small intestine cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>extraocular extension melanoma</keyword>
	<keyword>recurrent intraocular melanoma</keyword>
	<keyword>metastatic intraocular melanoma</keyword>
	<keyword>iris melanoma</keyword>
	<keyword>ciliary body choroid melanoma , medium/large size</keyword>
	<keyword>newly diagnose childhood ependymoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood pineoblastoma</keyword>
	<keyword>untreated childhood pineoblastoma</keyword>
	<keyword>adult pineal gland astrocytoma</keyword>
	<keyword>stage IIIA melanoma</keyword>
	<keyword>stage IIIB melanoma</keyword>
	<keyword>stage IIIC melanoma</keyword>
	<keyword>recurrent childhood anaplastic astrocytoma</keyword>
	<keyword>untreated childhood anaplastic astrocytoma</keyword>
	<keyword>recurrent childhood anaplastic oligoastrocytoma</keyword>
	<keyword>recurrent childhood anaplastic oligodendroglioma</keyword>
	<keyword>untreated childhood anaplastic oligoastrocytoma</keyword>
	<keyword>untreated childhood anaplastic oligodendroglioma</keyword>
	<keyword>recurrent childhood giant cell glioblastoma</keyword>
	<keyword>recurrent childhood glioblastoma</keyword>
	<keyword>untreated childhood giant cell glioblastoma</keyword>
	<keyword>untreated childhood glioblastoma</keyword>
	<keyword>recurrent childhood gliosarcoma</keyword>
	<keyword>untreated childhood gliosarcoma</keyword>
	<keyword>recurrent childhood gliomatosis cerebri</keyword>
	<keyword>untreated childhood gliomatosis cerebri</keyword>
	<keyword>childhood high-grade cerebellar astrocytoma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
</DOC>